Scorpion Therapeutics
Latest round
- Series C
Last raised
- Jul 2024
Total raised
- $380M
Investors
- 20
About Scorpion Therapeutics
Founded in 2020 and headquartered in Boston, US, Scorpion Therapeutics specializes in precision oncology, developing targeted therapies for cancer.5 billion.Scorpion Therapeutics specializes in precision oncology, primarily focusing on the development of transformational targeted therapies for patients with cancer. Its core product offering includes STX-478, a mutant-selective PI3Ka inhibitor currently in a Phase 1/2 clinical trial for treating breast cancer and other advanced solid tumors. STX-478 is designed to selectively inhibit the PI3Ka pathway in cancerous cells, addressing the unmet therapeutic needs of patients with hormone-positive breast cancers. Scorpion's pipeline also includes several other internally discovered clinical product candidates and discovery-stage programs targeting previously undruggable cancer pathways.Scorpion Therapeutics generates revenue through strategic partnerships and licensing agreements related to its innovative oncology therapies. The financial structure includes milestone payments tied to regulatory and clinical development benchmarks, along with potential royalties from future product sales. STX-478, as the flagship product, is expected to attract interest from healthcare providers and pharmaceutical partners due to its novel mechanism.Scorpion Therapeutics plans to leverage its recent acquisition by Eli Lilly and Company to expand its drug discovery efforts and enhance its oncology product pipeline. They are focused on advancing STX-478 and other pipeline candidates, with the goal of entering new markets and geographic regions, particularly in North America and Europe, by 2026. The acquisition is aimed at utilizing Eli Lilly's resources to support these initiatives, reinforcing Scorpion's commitment to developing innovative oncology treatments.
Who invested in Scorpion Therapeutics
20 investors across 3 rounds
See all investors in Scorpion Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Scorpion Therapeutics
Who invested in Scorpion Therapeutics?
Scorpion Therapeutics has 20 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Scorpion Therapeutics raised?
Scorpion Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Scorpion Therapeutics last raise money?
Scorpion Therapeutics's most recent round on record is a Series C, in Jul 2024.
What does Scorpion Therapeutics do?
Founded in 2020 and headquartered in Boston, US, Scorpion Therapeutics specializes in precision oncology, developing targeted therapies for cancer.
Where is Scorpion Therapeutics headquartered?
Scorpion Therapeutics is headquartered in Boston, US.
Which VCs invest in companies like Scorpion Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Scorpion Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Scorpion Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.